Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2018, the company owned and operated 421 care centers in 34 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:AMED
CUSIP02343610
Phone225-292-2031
Debt
Debt-to-Equity Ratio0.14
Current Ratio1.63
Quick Ratio1.63
Price-To-Earnings
Trailing P/E Ratio42.35
Forward P/E Ratio29.90
P/E Growth1.62
Sales & Book Value
Annual Sales$1.53 billion
Price / Sales2.08
Cash Flow$2.7518 per share
Price / Cash34.01
Book Value$15.22 per share
Price / Book6.15
Profitability
EPS (Most Recent Fiscal Year)$2.21
Net Income$30.30 million
Net Margins2.71%
Return on Equity16.83%
Return on Assets10.70%
Miscellaneous
Employees17,900
Outstanding Shares34,060,000
Market Cap$3,201.68
Amedisys (NASDAQ:AMED) Frequently Asked Questions
What is Amedisys' stock symbol?
Amedisys trades on the NASDAQ under the ticker symbol "AMED."
How were Amedisys' earnings last quarter?
Amedisys Inc (NASDAQ:AMED) posted its earnings results on Monday, May, 7th. The health services provider reported $0.79 EPS for the quarter, beating the consensus estimate of $0.67 by $0.12. The health services provider had revenue of $399.30 million for the quarter, compared to analysts' expectations of $395.38 million. Amedisys had a return on equity of 16.83% and a net margin of 2.71%. The firm's revenue was up 9.5% compared to the same quarter last year. During the same period last year, the firm earned $0.47 EPS. View Amedisys' Earnings History.
When is Amedisys' next earnings date?
What guidance has Amedisys issued on next quarter's earnings?
Amedisys issued an update on its FY18 earnings guidance on Monday, May, 7th. The company provided earnings per share (EPS) guidance of $2.97-$3.08 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.00. The company issued revenue guidance of $1.60-$1.64, compared to the consensus revenue estimate of $1.63 billion.
What price target have analysts set for AMED?
11 equities research analysts have issued 1-year price objectives for Amedisys' shares. Their forecasts range from $56.00 to $97.00. On average, they expect Amedisys' stock price to reach $71.50 in the next year. This suggests that the stock has a possible downside of 23.6%. View Analyst Ratings for Amedisys.
What is the consensus analysts' recommendation for Amedisys?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Are investors shorting Amedisys?
Amedisys saw a increase in short interest in the month of June. As of June 29th, there was short interest totalling 3,097,544 shares, an increase of 170.4% from the June 15th total of 1,145,586 shares. Based on an average daily volume of 320,481 shares, the days-to-cover ratio is presently 9.7 days. Approximately 9.2% of the company's stock are short sold. View Amedisys' Current Options Chain.
Who are some of Amedisys' key competitors?
Who are Amedisys' key executives?
Amedisys' management team includes the folowing people:
- Mr. Paul Berthold Kusserow, Pres, CEO & Director (Age 57)
- Mr. Scott G. Ginn, Chief Financial Officer (Age 49)
- Mr. Christopher T. Gerard, Chief Operating Officer (Age 51)
- Mr. Michael P. North, Chief Information Officer (Age 53)
- Mr. Pete Hartley, Chief Technology Officer and Sr. VP of Bus. Operations Systems
Has Amedisys been receiving favorable news coverage?
Media stories about AMED stock have been trending somewhat negative on Tuesday, Accern Sentiment reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Amedisys earned a coverage optimism score of -0.03 on Accern's scale. They also gave news coverage about the health services provider an impact score of 41.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Amedisys' major shareholders?
Amedisys' stock is owned by a variety of of institutional and retail investors. Top institutional investors include KKR CREDIT ADVISORS (US) LLC (7.60%), DnB Asset Management AS (0.21%), Bank of Montreal Can (0.06%), Mitsubishi UFJ Asset Management UK Ltd. (0.06%), Xact Kapitalforvaltning AB (0.01%) and Atria Investments LLC (0.01%). Company insiders that own Amedisys stock include Bruce D Perkins, David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Kkr Credit Advisors (Us) Llc, Lawrence R Pernosky, Michael Paul North and Scott G Ginn. View Institutional Ownership Trends for Amedisys.
Which institutional investors are selling Amedisys stock?
AMED stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can and DnB Asset Management AS. Company insiders that have sold Amedisys company stock in the last year include David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Kkr Credit Advisors (Us) Llc, Michael Paul North and Scott G Ginn. View Insider Buying and Selling for Amedisys.
Which institutional investors are buying Amedisys stock?
AMED stock was bought by a variety of institutional investors in the last quarter, including Mitsubishi UFJ Asset Management UK Ltd., Atria Investments LLC and Xact Kapitalforvaltning AB. View Insider Buying and Selling for Amedisys.
How do I buy shares of Amedisys?
Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amedisys' stock price today?
One share of AMED stock can currently be purchased for approximately $93.59.
How big of a company is Amedisys?
Amedisys has a market capitalization of $3.20 billion and generates $1.53 billion in revenue each year. The health services provider earns $30.30 million in net income (profit) each year or $2.21 on an earnings per share basis. Amedisys employs 17,900 workers across the globe.
How can I contact Amedisys?
Amedisys' mailing address is 3854 AMERICAN WAY, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]
MarketBeat Community Rating for Amedisys (NASDAQ AMED)
MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe AMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
